Innovative Metal-Organic Frameworks for Targeted Oral Cancer Therapy : A Review
Metal-organic frameworks (MOFs) have proven to be very effective carriers for drug delivery in various biological applications. In recent years, the development of hybrid nanostructures has made significant progress, including developing an innovative MOF-loaded nanocomposite with a highly porous structure and low toxicity that can be used to fabricate core-shell nanocomposites by combining complementary materials. This review study discusses using MOF materials in cancer treatment, imaging, and antibacterial effects, focusing on oral cancer cells. For patients with oral cancer, we offer a regular program for accurately designing and producing various anticancer and antibacterial agents to achieve maximum effectiveness and the lowest side effects. Also, we want to ensure that the anticancer agent works optimally and has as few side effects as possible before it is tested in vitro and in vivo. It is also essential that new anticancer drugs for cancer treatment are tested for efficacy and safety before they go into further research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Materials (Basel, Switzerland) - 16(2023), 13 vom: 29. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mousavi, Seyyed Mojtaba [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BioMOFs |
|---|
| Anmerkungen: |
Date Revised 18.07.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/ma16134685 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359457487 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359457487 | ||
| 003 | DE-627 | ||
| 005 | 20231226080922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ma16134685 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359457487 | ||
| 035 | |a (NLM)37444999 | ||
| 035 | |a (PII)4685 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mousavi, Seyyed Mojtaba |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Innovative Metal-Organic Frameworks for Targeted Oral Cancer Therapy |b A Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Metal-organic frameworks (MOFs) have proven to be very effective carriers for drug delivery in various biological applications. In recent years, the development of hybrid nanostructures has made significant progress, including developing an innovative MOF-loaded nanocomposite with a highly porous structure and low toxicity that can be used to fabricate core-shell nanocomposites by combining complementary materials. This review study discusses using MOF materials in cancer treatment, imaging, and antibacterial effects, focusing on oral cancer cells. For patients with oral cancer, we offer a regular program for accurately designing and producing various anticancer and antibacterial agents to achieve maximum effectiveness and the lowest side effects. Also, we want to ensure that the anticancer agent works optimally and has as few side effects as possible before it is tested in vitro and in vivo. It is also essential that new anticancer drugs for cancer treatment are tested for efficacy and safety before they go into further research | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BioMOFs | |
| 650 | 4 | |a metal-organic frameworks (MOFs) | |
| 650 | 4 | |a oral squamous cell carcinoma (OSCC) | |
| 700 | 1 | |a Hashemi, Seyyed Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Fallahi Nezhad, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Binazadeh, Mojtaba |e verfasserin |4 aut | |
| 700 | 1 | |a Dehdashtijahromi, Milad |e verfasserin |4 aut | |
| 700 | 1 | |a Omidifar, Navid |e verfasserin |4 aut | |
| 700 | 1 | |a Ghahramani, Yasamin |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Chin Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Chiang, Wei-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Gholami, Ahmad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Materials (Basel, Switzerland) |d 2009 |g 16(2023), 13 vom: 29. Juni |w (DE-627)NLM208535349 |x 1996-1944 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:13 |g day:29 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ma16134685 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 13 |b 29 |c 06 | ||